Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events "ADANCE"

Not yet recruiting

Phase 2/3 Results N/A

Summary of Purpose

Nondisabling cerebrovascular events represent the largest group of cerebrovascular disease with a high risk of recurrent stroke. A recent trial indicated that clopidogrel and aspirin treatment reduced the risk of recurrent stroke and was not associated with increased hemorrhage events, compared with aspirin monotherapy. Apixaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 13 August 2013.

1 Jan 2014 13 Aug 2013 1 Dec 2015 1 Jul 2016 1 Aug 2013 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions See All

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts